Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02274038 · ClinicalTrials.gov registry record · NA

Serial [18F]Thymidine (FLT)PET/CT as a Biomarker of Response in Pemetrexed Therapy for Non-Small Cell Lung Cancer

A NA study, sponsored by University of Pennsylvania.

Terminated
Registry status
NA
Development phase
3
Enrollment target

NCT02274038: Clinical Trial NA study, sponsored by University of Pennsylvania.

NCT02274038 is a NA study that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 3 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT02274038, a NA study, was terminated before completion, sponsored by University of Pennsylvania.

TERMINATED
Registry status
NA
Development phase
3 participants
Enrollment target

Study Summary

The investigators will test the hypothesis that positron emission tomography (PET) imaging with the imaging agent 18F-thymidine (FLT) can rapidly assess treatment response in patients with unresectable non-small cell lung cancer (NSCLC).

Primary Outcome

A baseline FLT-PET/CT will be performed prior to starting pemetrexed therapy. This scan will be used to compare to post therapy FLT-PET/CT in order to assess change in tumor accumulation of FLT.

Interventions

  • DRUG Baseline 18F-thymidine (FLT) PET/CT
  • DRUG Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced tumor FLT "flare"
  • DRUG Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced changes in tumor proliferation

Trial Details

FieldValue
Enrollment Target 3 participants
Start Date 2015-03
Est. Completion 2018-07
Phase NA
University of Pennsylvania

1,423 total trials

Why NCT02274038 stopped before completion

NCT02274038 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).

The record links to 0 conditions, and to 3 interventions - of which Baseline 18F-thymidine (FLT) PET/CT is the first listed.

NCT02274038 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02274038 about?

NCT02274038 is a clinical study titled "Serial [18F]Thymidine (FLT)PET/CT as a Biomarker of Response in Pemetrexed Therapy for Non-Small Cell Lung Cancer". The investigators will test the hypothesis that positron emission tomography (PET) imaging with the imaging agent 18F-thymidine (FLT) can rapidly assess treatment response in patients with unresectable non-small cell lung cancer (NSCLC).

What is the current status of trial NCT02274038?

This trial is currently terminated. It is a NA study. The enrollment target is 3 participants. The study started on 2015-03. Estimated completion is 2018-07.

What interventions are being tested in trial NCT02274038?

The interventions under investigation include: Baseline 18F-thymidine (FLT) PET/CT (DRUG), Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced tumor FLT "flare" (DRUG), Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced changes in tumor proliferation (DRUG).

Who is sponsoring clinical trial NCT02274038?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02274038's enrollment target sits among peer trials

3 1996th of 2000 higher than 4 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02274038, the US trial registry maintained by the National Library of Medicine. NCT02274038 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.